GSK (LON:GSK) Insider Anne Beal Acquires 196 Shares of Stock

GSK plc (LON:GSK) insider Anne Beal acquired 196 shares of GSK stock in a transaction that occurred on Friday, March 20th. The stock was purchased at an average cost of GBX 5,179 per share, with a total value of £10,150.84.

GSK Trading Down 0.6%

Shares of GSK stock opened at GBX 1,939 on Tuesday. GSK plc has a fifty-two week low of GBX 1,242.50 and a fifty-two week high of GBX 2,282. The company has a debt-to-equity ratio of 108.20, a quick ratio of 0.73 and a current ratio of 0.82. The stock’s fifty day moving average is GBX 2,026.08 and its two-hundred day moving average is GBX 1,820.75. The firm has a market capitalization of £77.78 billion, a P/E ratio of 13.97, a PEG ratio of 1.24 and a beta of 0.32.

GSK (LON:GSK) last released its earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share (EPS) for the quarter. GSK had a net margin of 17.50% and a return on equity of 37.19%. Research analysts expect that GSK plc will post 175.980975 earnings per share for the current fiscal year.

Key Headlines Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Senior insiders bought stock this week, signaling confidence from management: Jonathan Symonds purchased 5,000 shares at GBX 1,951 (~£97,550), Wendy Becker bought 411 shares at GBX 1,963 (~£8,068) and Anne Beal bought 196 shares (reported at GBX 5,179) — insider buying often suggests executives view the shares as undervalued.
• Positive Sentiment: GSK expanded its buyback program and increased treasury holdings, repurchasing 560,000 ordinary shares on 20 March (via BNP), which reduces float and supports EPS. Article Title
• Positive Sentiment: Regulatory progress: GSK’s lung cancer treatment received orphan drug designation in Japan, which can enable regulatory incentives, market exclusivity and a faster development path in that market. Article Title
• Neutral Sentiment: GSK admitted 96,525 new ordinary shares to trading under employee share plans — standard issuance for employee compensation; modest dilution but typical and usually neutral for near-term valuation. Article Title

Wall Street Analyst Weigh In

GSK has been the subject of a number of recent research reports. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Berenberg Bank boosted their target price on GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a report on Monday, November 24th. Jefferies Financial Group restated a “buy” rating and issued a GBX 2,100 price target on shares of GSK in a research report on Wednesday, January 7th. UBS Group reaffirmed a “neutral” rating and issued a GBX 1,940 price target on shares of GSK in a report on Friday, January 23rd. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a research report on Thursday, January 15th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, GSK presently has a consensus rating of “Hold” and an average price target of GBX 1,917.86.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.